Sign in
8-K

Current Report

Adaptimmune Therapeutics PLC Filed Acc 0001104659-25-071009

Material agreement · Exit or restructuring costs · Executive or director change · Regulation FD disclosure

  • Item 1.01 Entry into a material definitive agreement
  • Item 2.05 Costs associated with exit or disposal activities
  • Item 5.02 Departure or appointment of directors or officers
  • Item 7.01 Regulation FD disclosure

From the SEC's structured data for this filing

Loading tm2521829d1_8k.htm…